Resources
74 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/12/2024
This peer reviewed journal article OUD treatment and pregnancy outcomes among pregnant patients receiving OUD care through a telehealth addiction treatment program in the US. The patients identified in the study received buprenorphine or buprenorphine and naloxone treatment.
Posted 3/29/2024
The Centers for Disease Control and Prevention (CDC) has naloxone trainings and fact sheets available for clinicians. The trainings and fact sheets can help clinicians raise awareness about the benefits of naloxone by talking with patients and their family, friends, and caregivers.
Posted 3/10/2024 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration's (SAMHSA) updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. It emphasizes harm reduction and access to treatment as essential aspects of overdose prevention.
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.
Posted 11/9/2023 (updated 3/28/2024)
The CDC has released updated HCV testing recommendations perinatally exposed infants and children.
Posted 10/23/2023 (updated 3/27/2024)
Posted 10/15/2023 (updated 3/27/2024)
The University of Rochester Recovery Center of Excellence, one of three FORHP-supported Rural Centers of Excellence on Substance Use Disorder, has developed comprehensive training on the treatment of opioid use disorder (OUD) in primary care. This no-cost training prepares providers and staff to deliver evidence-based care to patients. Continuing education credits are available.
Posted 9/29/2023 (updated 3/27/2024)
The 2023 RCORP-Overdose Response Onboarding Packet contains strategies and resources to assist grantees in the implementation of your new Overdose Response (OR) grant. The Onboarding Packet includes tools to support grant-funded activities, along with information on accessing TA.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
RSV 2023 Session: Quick Response Teams: Preventing Deaths While Sharing the Hope of Recovery (Day 1)
Posted 7/26/2023 (updated 3/28/2024)
The presentation discussed the development and changes in the utilization of a Quick Response Team in an Ohio rural community.